Pharmacokinetics of prolonged infusion of high-dose dexmedetomidine in critically ill patients

Critical Care

Volumn 15, Issue 5, 2011, Pages

  Iirola, Timo ^a   Aantaa, Riku ^a   Laitio, Ruut ^a   Kentala, Erkki ^a   Lahtinen, Maria ^a   Wighton, Andrew ^b   Garratt, Chris ^b   Ahtola Sätilä, Tuula ^c   Olkkola, Klaus T ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b Orion Pharma R and D   (United Kingdom)

^c ORION CORPORATION   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

DEXMEDETOMIDINE; DRUG METABOLITE; FENTANYL; OXYCODONE; HYPNOTIC SEDATIVE AGENT;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INTENSIVE CARE; MALE; PAIN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; STEADY STATE; ADOLESCENT; CRITICAL ILLNESS; DOSE RESPONSE; HALF LIFE TIME; INTRAVENOUS DRUG ADMINISTRATION; METABOLIC CLEARANCE RATE; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CRITICAL ILLNESS; DEXMEDETOMIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HALF-LIFE; HUMANS; HYPNOTICS AND SEDATIVES; INFUSIONS, INTRAVENOUS; METABOLIC CLEARANCE RATE; MIDDLE AGED;

EID: 83155172637     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc10518     Document Type: Article

References (21)

1. Devlin JW, Mallow-Corbett S, Riker RR. Adverse drug events associated with the use of analgesics, sedatives, and antipsychotics in the intensive care unit. Crit Care Med 2010, 38:S231-S243.
2. Karol MD, Maze M. Pharmacokinetics and interaction pharmacodynamics of dexmedetomidine in humans. Baillières Clin Anaesthesiol 2000, 14:261-269.
3. Dutta S, Lal R, Karol MD, Cohen T, Ebert T. Influence of cardiac output on dexmedetomidine pharmacokinetics. J Pharm Sci 2000, 89:519-527. 10.1002/(SICI)1520-6017(200004)89:4<519::AID-JPS9>3.0.CO;2-U, 10737913.
4. Orion Corporation Dexdor® [summary of product characteristics]. 2011, Espoo, Finland: Orion Corporation, Orion Corporation.
5. Hayashi Y, Maze M. Alpha 2 adrenoceptor agonists and anaesthesia. Br J Anaesth 1993, 71:108-118. 10.1093/bja/71.1.108, 8102063.
6. Venn RM, Karol MD, Grounds RM. Pharmacokinetics of dexmedetomidine infusions for sedation of postoperative patients requiring intensive care. Br J Anaesth 2002, 88:669-675. 10.1093/bja/88.5.669, 12067004.
7. Sessler CN, Gosnell MS, Grap MJ, Brophy GM, O'Neal PV, Keane KA, Tesoro EP, Elswick RK. The Richmond Agitation-Sedation Scale: validity and reliability in adult intensive care unit patients. Am J Respir Crit Care Med 2002, 166:1338-1344. 10.1164/rccm.2107138, 12421743.
8. Ji QC, Zhou JY, Gonzales RJ, Gage EM, El-Shourbagy TA. Simultaneous quantitation of dexmedetomidine and glucuronide metabolites (G-Dex-1 and G-Dex-2) in human plasma utilizing liquid chromatography with tandem mass spectrometric detection. Rapid Commun Mass Spectrom 2004, 18:1753-1760. 10.1002/rcm.1548, 15282775.
9. Rowland M, Tozer TN. Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications 2011, Philadelphia: Lippincott Williams and Wilkins, 4.
10. Clinical Safety Data Management: Definitions and Standards for Expedited Reporting. , http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002749.pdf
11. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993, 270:2957-2963. 10.1001/jama.270.24.2957, 8254858.
12. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003, 139:137-147.
13. Brocks DR, Mehvar R. Rate and extent of drug accumulation after multiple dosing revisited. Clin Pharmacokinet 2010, 49:421-438. 10.2165/11531190-000000000-00000, 20528003.
14. Dyck JB, Maze M, Haack C, Vuorilehto L, Shafer SL. The pharmacokinetics and hemodynamic effects of intravenous and intramuscular dexmedetomidine hydrochloride in adult human volunteers. Anesthesiology 1993, 78:813-820. 10.1097/00000542-199305000-00002, 8098190.
15. Anttila M, Penttila J, Helminen A, Vuorilehto L, Scheinin H. Bioavailability of dexmedetomidine after extravascular doses in healthy subjects. Br J Clin Pharmacol 2003, 56:691-693. 10.1046/j.1365-2125.2003.01944.x, 1884292, 14616431.
16. Ebert TJ, Hall JE, Barney JA, Uhrich TD, Colinco MD. The effects of increasing plasma concentrations of dexmedetomidine in humans. Anesthesiology 2000, 93:382-394. 10.1097/00000542-200008000-00016, 10910487.
17. De Wolf AM, Fragen RJ, Avram MJ, Fitzgerald PC, Rahimi-Danesh F. The pharmacokinetics of dexmedetomidine in volunteers with severe renal impairment. Anesth Analg 2001, 93:1205-1209. 10.1097/00000539-200111000-00031, 11682398.
18. Ruokonen E, Parviainen I, Jakob SM, Nunes S, Kaukonen M, Shepherd ST, Sarapohja T, Bratty JR, Takala J. Dexmedetomidine versus propofol/midazolam for long-term sedation during mechanical ventilation. Intensive Care Med 2009, 35:282-290. 10.1007/s00134-008-1296-0, 18795253.
19. Annane D, Sebille V, Duboc D, Le Heuzey JY, Sadoul N, Bouvier E, Bellissant E. Incidence and prognosis of sustained arrhythmias in critically ill patients. Am J Respir Crit Care Med 2008, 178:20-25. 10.1164/rccm.200701-031OC, 18388358.
20. Hammer GB, Drover DR, Cao H, Jackson E, Williams GD, Ramamoorthy C, Van Hare GF, Niksch A, Dubin AM. The effects of dexmedetomidine on cardiac electrophysiology in children. Anesth Analg 2008, 106:79-83. 10.1213/01.ane.0000297421.92857.4e, 18165557.
21. Jones GM, Murphy CV, Gerlach AT, Goodman EM, Pell LJ. High-dose dexmedetomidine for sedation in the intensive care unit: an evaluation of clinical efficacy and safety. Ann Pharmacother 2011, 45:740-747. 10.1345/aph.1P726, 21666095.